[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platinum-resistant-recurrent-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platinum-resistant-recurrent-ovarian-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,79,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100638290","phase-2-liposomal-irinotecan-plus-enlonstobart-for-platinum-resistant-recurrent-ovarian-cancer-100638290",false,"NCT07591831","Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer","An Exploratory Clinical Study of Liposomal Irinotecan Combined With Enlonstobart in Patients With Platinum-Resistant Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Female participants aged 18 to 75 years, inclusive, at the time of signing informed consent.\n2. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, FIGO stage II-IV.\n3. Platinum-resistant recurrent disease, defined as disease progression within 6 months after the last platinum-containing chemotherapy, and not platinum-refractory disease, defined as disease progression within 4 weeks after initial platinum-containing chemotherapy. Participants may have received up to two prior lines of non-platinum systemic therapy. Treatment with a PARP inhibitor or anti-angiogenic therapy after platinum-resistant recurrence will be counted as one line of therapy; maintenance treatment with a PARP inhibitor or anti-angiogenic therapy will not be counted as a treatment line.\n4. Ability to provide sufficient qualified formalin-fixed paraffin-embedded tumor tissue samples or slides for PD-L1 testing. Participants who are unable to provide tumor tissue slides for certain reasons may be enrolled at the investigator's discretion.\n5. At least one measurable lesion at baseline according to RECIST version 1.1. The measurable lesion must not have received prior local therapy such as radiotherapy. A lesion located within a previously irradiated area may be selected as a target lesion if disease progression has been confirmed.\n6. ECOG performance status of 0 or 1.\n7. Expected survival of at least 3 months.\n8. Adequate organ function, meeting all of the following criteria without blood transfusion, hematopoietic stimulating factors, or medication correction of blood cell counts within 14 days before the first dose:\n\n   1. Absolute neutrophil count ≥1.5 × 10\\^9\u002FL;\n   2. Platelet count ≥75 × 10\\^9\u002FL;\n   3. Hemoglobin ≥9 g\u002FdL;\n   4. Serum creatinine ≤1.5 × the upper limit of normal or creatinine clearance ≥50 mL\u002Fmin;\n   5. Total bilirubin ≤1.5 × the upper limit of normal, or ≤3 × the upper limit of normal for participants with Gilbert's syndrome;\n   6. Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal, or ≤5 × the upper limit of normal for participants with liver metastases;\n   7. Activated partial thromboplastin time and international normalized ratio ≤1.5 × the upper limit of normal, without anticoagulants or other drugs affecting coagulation function within 14 days before the first dose, except for participants requiring long-term anticoagulation due to underlying disease.\n9. Toxicities caused by prior antitumor therapy must have recovered to Grade 1 or lower according to CTCAE version 5.0, except for residual alopecia and fatigue.\n10. Participants must understand the study and voluntarily sign written informed consent before study entry.\n\nExclusion Criteria:\n\n1. History of severe hypersensitivity reaction to monoclonal antibody preparations or uncontrolled allergic asthma.\n2. Known untreated central nervous system metastases, or treated but still symptomatic central nervous system metastases. Participants with residual signs or symptoms related to central nervous system treatment may be eligible if neurological symptoms have been stable or improved for at least 2 weeks before screening.\n3. History of primary immunodeficiency.\n4. Active autoimmune disease or history of autoimmune disease. Participants with well-controlled type 1 diabetes mellitus, well-controlled hypothyroidism requiring only hormone replacement therapy, skin diseases not requiring systemic treatment such as vitiligo, psoriasis, or alopecia, or conditions not expected to recur without external triggers may be eligible for further screening.\n5. Serious arterial or venous thrombotic events within 3 months before screening, such as transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep venous thrombosis, or pulmonary embolism.\n6. History of interstitial lung disease, except localized radiation-induced interstitial pneumonia, or noninfectious pneumonia requiring glucocorticoid therapy.\n7. Prior treatment with any antibody or drug targeting T-cell costimulatory or immune checkpoint pathways, including PD-1, PD-L1, PD-L2, CTLA-4, OX40, or CD137 inhibitors.\n8. Prior immune-related adverse event of CTCAE version 5.0 Grade 3 or higher after immunotherapy.\n9. Major surgery or radical radiotherapy within 28 days before the first dose; palliative radiotherapy within 14 days before the first dose; or use of radiopharmaceuticals such as strontium or samarium within 56 days before the first dose.\n10. Systemic antitumor therapy within 28 days before the first dose, including but not limited to chemotherapy, immunotherapy, macromolecular targeted therapy, or biological therapy such as tumor vaccines, cytokines, or growth factors used to control cancer. Small-molecule targeted therapy or oral fluoropyrimidines within 14 days before the first dose or within 5 half-lives, whichever is longer; or mitomycin C or nitrosoureas within 6 weeks before the first dose.\n11. Receipt of a live attenuated vaccine within 28 days before the first dose or planned receipt of a live attenuated vaccine during the study.\n12. Any active infection requiring systemic treatment by intravenous infusion within 28 days before the first dose.\n13. Treatment within 14 days before the first dose with traditional Chinese patent medicines approved by the NMPA whose package inserts clearly state antitumor indications, or traditional Chinese herbal medicine documented in the medical record as being used for antitumor purposes.\n14. Whole blood or blood component transfusion within 14 days before the first dose.\n15. Treatment with glucocorticoids equivalent to prednisone \\>10 mg\u002Fday or other immunosuppressive agents within 14 days before the first dose.\n16. Participation in another clinical trial and receipt of investigational treatment within 28 days before the first dose, calculated from the date of the last treatment in the previous clinical study, except participation in overall survival follow-up of a study.\n17. Positive human immunodeficiency virus antibody or Treponema pallidum antibody; positive hepatitis B surface antigen and\u002For hepatitis B core antibody with hepatitis B virus DNA above the upper limit of normal of the testing laboratory; or positive hepatitis C antibody with hepatitis C virus RNA above the upper limit of normal of the testing laboratory.\n18. History of active tuberculosis.\n19. Pregnancy or breastfeeding.\n20. Other malignancy that progressed or required treatment within 5 years before screening, except adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or cured carcinoma in situ such as breast carcinoma in situ.\n21. Any other condition that may increase the risk associated with study treatment, interfere with interpretation of study results, affect study compliance, or otherwise make the participant unsuitable for the study in the investigator's judgment.\n22. Any clinically significant gastrointestinal disease, including liver disease, bleeding, inflammation, obstruction, or diarrhea greater than Grade 2.\n23. Current use or use within the past 2 weeks of strong CYP3A enzyme inducers or inhibitors and\u002For strong UGT1A inhibitors.\n24. Prior use of liposomal irinotecan formulation or irinotecan.\n25. Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.","FEMALE","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian cancer.\n\nEligible female participants with histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, FIGO stage II-IV, will receive liposomal irinotecan and enlonstobart every 2 weeks. Tumor assessment will be performed every 8 weeks. Participants may discontinue study treatment in the event of disease progression, intolerable toxicity, withdrawal of consent, or other reasons judged by the investigator.",[27,28,29,30],"Platinum-resistant Recurrent Ovarian Cancer","Fallopian Tube Cancers","Epithelial Ovarian Cancer","Primary Peritoneal Cancer",[32,33,34,35,36,37,38,39,40,41,42],"Platinum-resistant ovarian cancer","Recurrent ovarian cancer","Epithelial ovarian cancer","Fallopian tube cancer","Primary peritoneal cancer","Liposomal irinotecan","Enlonstobart","PD-1 inhibitor","Objective response rate","Progression-free survival","Overall survival","NOT_YET_RECRUITING","2026-05-15",{"date":46,"type":47},"2026-05-18","ACTUAL",{"date":49,"type":21},"2026-05-30",{"date":51,"type":21},"2030-05-30",{"name":53,"class":54},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100549483","phase-2-a-study-of-b013-in-combination-with-paclitaxel-in-patients-with-platinum-resistant-recurrent-ovarian-cancer-100549483","NCT06434610","A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.","Inclusion Criteria:\n\n1. Subjects who voluntarily participate in this study and sign informed consent form;\n2. Ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histopathological examination and meeting the criteria for platinum resistance recurrence;\n3. ECOG performance status of 0 or 1；\n4. Expected survival \\> 12 weeks;\n5. The subject has at least one measurable lesion;\n6. Normal function of major organs;\n7. The fertile subjects agree to use reliable contraception from signing the informed consent to at least 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Subjects who have received prescribed treatment previously;\n2. Subjects who are still using anti-tumor traditional Chinese patent medicines at the time of signing informed consent;\n3. Subjects with known central nervous system metastasis and multiple bone metastasis;\n4. Subjects who had clinical symptoms of pleural effusion, pericardial effusion or ascites before randomization and needed puncture drainage, or had received puncture drainage within the previous 2 weeks;\n5. Have a history of other malignant tumors within 5 years before signing the informed consent;\n6. Subjects with prescribed cardiovascular diseases;\n7. Subjects with infections requiring intravenous antibiotic infusion within 2 weeks prior to randomization;\n8. Had severe lung disease before randomization;\n9. Before randomization, the peripheral nerve toxicity of previous anti-tumor treatment was \\> grade 2, and other reversible toxicity was \\> grade 1;\n10. Subjects who had undergone surgery within 28 days prior to randomization and did not recover from adverse effects of surgery;\n11. Subjects who participated in clinical trials within 30 days prior to randomization and received other unmarketed investigational drugs;\n12. Subjects who are known to be allergic to any component of B013 or paclitaxel.\n13. Subjects with a known history of substance abuse, alcohol or drug use; Subjects with a known history of neurological or psychiatric disorders;\n14. Female subjects who are pregnant or breastfeeding;\n15. Other situations determined by the researchers and\u002For sponsors as unsuitable for participation in this trial.",{"count":63,"type":21},90,[24],"To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.",[27],"RECRUITING","2026-04-29",{"date":70,"type":47},"2026-05-05",{"date":72,"type":47},"2024-07-11",{"date":74,"type":21},"2026-12-31",{"name":76,"class":77},"Shanghai Jiaolian Drug Research and Development Co., Ltd","INDUSTRY",17,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100568887","phase-1-apg-2449-monotherapy-or-in-combination-with-pld-in-patients-with-platinum-resistant-recurrent-oc-or-advanced-st-100568887","NCT06687070","APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449 Monotherapy or in Combination With Anticancer Agents in Patients With Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors","Inclusion Criteria:\n\n1. Part A: No gender limitation. Patients with histologically and\u002For cytologically confirmed ALK\u002FROS1 gene fusion positive non-small cell lung cancer and various advanced tumors.\n\n   Part B: Female only. Histologically proven ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.\n2. At least one measurable tumor lesion.\n3. ECOG score is 0\\~1.\n4. Life expectancy of ≥3 months.\n5. AE caused by previous treatment must recover to ≤ grade 1.\n6. Sufficient bone marrow, liver, kidney and coagulation function.\n7. Female patients must be in a non-pregnant and non-lactating state.\n8. Able to understand and willing to sign informed consent.\n9. Patients are required to provide fresh or archived tumor tissue samples prior to treatment.\n\nExclusion Criteria:\n\n1. Undergone major surgery or major trauma within 28 days before first dose or a diagnostic biopsy within 14 days before first dose.\n2. Received systemic antitumor drugs, including investigational drugs.\n3. Received radiotherapy within 14 days before first dose.\n4. Previous treatment with FAK inhibitors.\n5. Have tumors at positions other than existing ovarian cancer or of other histological types within 3 years before first dose.\n6. Known active central nervous system (CNS) metastases and\u002For cancerous meningitis.\n7. Major cardiovascular and cerebrovascular disease occurred within 6 months before first dose.\n8. Patients with pleural effusion, pericardial effusion, or ascites requiring puncture, drainage, or having received drainage within 1 month before first dose.\n9. Malabsorption syndrome, or inability to take medications orally.\n10. Severe gastrointestinal disease.\n11. Any serious or uncontrolled systemic disease; Various chronic active infections.\n12. Allergy to APG-2449 or PLD and its drug components.\n13. Previous cumulative doses of anthracyclines ≥550 mg\u002Fm\\^2.\n14. Patients using a moderately potent CYP3A4, CYP2C9, or CYP2C19 inhibitor\u002Finducer or P-gp inhibitor within a week before first dose. Patients using CYP3A4 substrates and the drugs of a narrow treatment window within a week before first dose.\n15. Other factors that, in the investigator's judgment, should prevent the patient from entering the study.","ALL",{"count":88,"type":21},50,[90],"PHASE1","An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.",[27,93],"Advanced Solid Tumor",[95],"APG-2449","2025-02-24",{"date":98,"type":47},"2025-02-26",{"date":100,"type":47},"2024-12-17",{"date":102,"type":21},"2027-05",{"name":104,"class":77},"Ascentage Pharma Group Inc.",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100555275","phase-2-a-study-of-ql1706-an-anti-pd-1ctla-4-combined-antibody-combined-with-albumin-bound-paclitaxel-and-bevacizumab-in-the-treatment-of-platinum-resistant-recurrent-ovarian-cancer-100555275","NCT06509971","A Study of QL1706 (an Anti-PD-1\u002FCTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Voluntary signing of a written ICF.\n2. Age ≥18 years, ≤75 years, female.\n3. The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0 or 1.\n4. Expected survival ≥3 months.\n5. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.\n6. Patients with platinum-resistant recurrent ovarian cancer (including fallopian tube and peritoneal cancer) were defined as progression within 6 months after platinum-based chemotherapy.\n7. At least one measurable lesion according to RECIST v1.1, and this lesion is amenable to repeated accurate measurements according to RECIST v1.1. Lesions that have received radiation therapy can be considered as target lesions if they are clearly progressive and measurable on the basis of imaging.\n8. Determination of good organ function through the following requirements:\n\n   A) hematology (no blood component and cell growth factor support therapy was used for 7 days before study initiation) :\n\n   I. ANC ≥1.5 × 109 L (1.500 MM3) in absolute neutrophil; II. Platelet count ≥100 × 109\u002FL (100,000\u002FMM3) ; III. Hemoglobin ≥90 g\u002FL.\n\n   B) kidneys:\n\n   I. Creatinine clearance \\* (CrCl) calculated value ≥50 mL\u002Fmin\n\n   \\* CrCl (Cockcroft-gault formula) will be calculated using Cockcroft-Gault formula CrCL (mL\u002Fmin) = \\[(140-age) × weight (kg) × f \\]\u002F(SCR (mg\u002FdL) × 72) F = 0.85; SCR = serum creatinine. II. Urine protein \\\u003C 2 + or 24 h (h) urine protein quantification \\\u003C 1.0 g.\n\n   C) liver:\n\n   I. Serum total bilirubin (TBil)≤1.5 × ULN II. AST and ALT ≤2.5 × ULN III. Alb (Alb)≥28GL\n\n   D) coagulation function:\n\n   I. International standard ratio (INR) and activated partial thromboplastin time (APTT)≤1.5 × ULN.\n\n   E) cardiac function:\n\n   I. Left ventricular ejection fraction (LVEF)≥50% .\n9. A fertile female subject must have a urine or serum pregnancy test within 3 days before the first dose (if the urine pregnancy test result can not be confirmed as negative, a serum pregnancy test is required, whichever is the serum pregnancy result) , and the results were negative. If a fertile female subject has sex with an unsterilized male partner, the subject must use an acceptable method of contraception from the beginning of the screening process, consent must also be given to the method of contraception used prior to its continued use for 120 days after the last administration of the study drug; discontinuation of contraception after this time point should be discussed with the investigator.\n10. Subjects were willing and able to comply with schedule visits, treatment protocols, laboratory tests, and other requirements of the study.\n\nExclusion Criteria:\n\n1. Ovarian cancer of non-epithelial origin, fallopian tube cancer, primary peritoneal cancer (such as germ cell tumors) , and low-malignant potential ovarian tumors (such as borderline tumors) .\n2. Previous (within 5 years) or concurrent with other malignancies, the local tumors that have been cured (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, etc.) and breast cancer that has not recurred for more than 3 years after radical operation are excluded.\n3. Local recurrence is suitable for patients undergoing surgery.\n4. Previous radiation therapy of the abdomen and pelvis.\n5. Had received immunotherapy in the past, these include immune-checkpoint inhibitors (such as PD-1 CTLA-4 Bispecific monoclonal antibody, which allow previous use of PD-1 or PD-L1 mabs) , immune-checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.) , and immune-cell therapies for any of the mechanisms of tumor immunity.\n6. Patients who were known to be allergic to any component of any investigational drug, had a history of severe hypersensitivity to other monoclonal antibody, and were known to have permanently discontinued the relevant therapeutic drug could not be enrolled.\n7. Participated in the treatment of an experimental drug or used an experimental device within 4 weeks before the first study administration.\n8. One week before the first dose (or 5 drug half-lives, whichever is longer) , a potent or intermediate CYP3A4 inhibitor, a P-gp or a BCRP inhibitor were received.\n9. Last systemic anti-tumor therapy, including chemotherapy, bevacizumab or its bioanalogues, was given within 3 weeks before the first dose, and anti-tumor hormone therapy was given within 2 weeks before the first dose Non-target lesions were treated with palliative local therapy within 2 weeks before the first dose Received Hapten therapy (such as interleukin, interferon, and thymosin, not including Il-11 for thrombocytopenia) within 2 weeks before the first dose; Within 1 week before the first administration, she had received Chinese herbal medicine or Chinese patent medicine with anti-tumor indication.\n10. Use of systemic glucocorticoid or other immunosuppressive drug within one week prior to initial administration, systemic glucocorticoid (i.e. not more than 10mg daily prednisone or equivalent dose of other glucocorticoid) that do not include nasal spray, inhalation or other route local glucocorticoid or physiological doses, allow for symptoms of dyspnea due to diseases such as chronic obstructive pulmonary disease, and temporary use of glucocorticoid for allergy prevention.\n11. The live vaccine was administered within 30 days of the first dose, or was planned for the duration of the study.\n12. Has an active autoimmune disease that requires systemic treatment in the past two years (such as use of disease-modifying drugs, corticosteroid, immunosuppressive therapy) , replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency) is not considered a systemic treatment.\n13. Active or previous history of a well-defined inflammatory bowel disease such as Crohn's disease, ulcerative colitis or chronic diarrhea.\n14. History of immunodeficiency, HIV antibody positive, current long-term use of systemic corticosteroid or other immunosuppressive agents.\n15. Subjects with known active tuberculosis (TB) and suspected active TB should be excluded by clinical examination.\n16. Known active syphilis infection.\n17. Known history of organ transplants and Hematopoietic stem cell transplants.\n18. Previous history of non-infectious pneumoniainterstitial lung disease requiring systemic glucocorticoid therapy or current presence of non-infectious pneumonia.\n19. Severe infection occurred within 4 weeks before the first dose, including but not limited to complications, sepsis, or severe pneumonia requiring hospitalization; Active infection (excluding antiviral therapy for hepatitis B or C) that has received systemic anti-infective therapy within 2 weeks before the first dose.\n20. Untreated subjects with active hepatitis B (HBsAg positive and HBV-DNA \\> 1000 copies\u002Fml (200 IU\u002Fml or above the lower limit of detection, whichever is higher) were required to receive anti-hbv therapy during study treatment for those with hepatitis B; and active hepatitis C subjects (HCV antibody positive and HCV-rna levels above the lower limit of detection) .\n21. Those who had a major surgical procedure or major trauma within 30 days before the first dose, or who had a major surgical plan within 30 days after the first dose (at the investigator's discretion) ; Minor local procedures (excluding central venous catheterization via peripheral venipuncture and intravenous port implantation) were performed within 3 days before the first dose.\n22. Known presence of central nervous system metastases, meningeal metastases, spinal cord metastases or compression.\n23. Subjects with clinical symptoms or repeated drainage of pleural effusion, pericardial effusion, or ascites.\n24. There are currently uncontrolled co-morbidities, these include, but are not limited to, symptomatic heart failure (grade 2 or higher according to the New York Heart Association functional class) , unstable angina, acute myocardial ischemia, poorly controlled arrhythmias, decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease, or gastritis, psychiatric\u002Fsocial conditions that may limit subjects' ability to comply with research requirements or affect their ability to provide written informed consent.\n25. Uncontrolled hypertension, systolic blood pressure \\> 140 mmhg or diastolic blood pressure \\> 90 mmhg after optimal medical treatment, history of Hypertensive crisis or hypertensive encephalopathy.\n26. Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia. Unstable angina, myocardial infarction, heart failure or vascular disease (such as a ruptured aortic aneurysm) that requires hospitalization within 12 months of the first dose, or other cardiac lesions (such as poorly controlled arrhythmias, myocardial ischemia) that may affect the safety evaluation of the study drug.\n27. Esophageal Gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding, extensive bowel resection (partial or extensive colectomy with chronic diarrhea) , Crohn's disease, ulcerative colitis or chronic diarrhea.\n28. Any arterial thromboembolic event, NCI CTCAE version 5.0 Grade 3 or greater, venous thromboembolism, transient cerebral ischemia, or cerebrovascular accident occurred within 6 months before the first dose.\n29. Acute exacerbation of chronic obstructive pulmonary disease within 1 month of first dose.\n30. Patients with any sign of bleeding constitution, regardless of severity; patients with any bleeding or bleeding event ≥ CTCAE grade 3 within 4 weeks before the first dose.\n31. Current imaging or clinical manifestations of gastrointestinal obstruction, including incomplete obstruction.\n32. Severe bleeding tendency or Coagulopathy, or receiving thrombolytic therapy. Aspirin (\\> 325mg daily) or dipyrimidine, ticlopidine, clopidogrel, and Cilostazol are currently used or have been used recently (within 10 days before the first dose of study treatment) , and anticoagulants that require monitoring of INR (such as Warfarin) .\n33. Imaging showed that the tumor had surrounded or invaded important blood vessels, or that it was highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study, compression of the superior vena cava, inferior vena cava or invasion of the heart.\n34. Toxicities from previous antitumour therapy did not resolve, defined as toxicities that did not return to grade 0 or 1 of NCI CTCAE version 5.0, or levels specified in the inclusion\u002Fexclusion criteria; Except for alopecia and sequelae of neurotoxicity related to previous platinum therapy. For subjects who develop irreversible toxicity and are not expected to worsen after administration of the study drug (EG, hearing loss) , it may be included in the study after consultation with the medical examiner.\n35. Local or systemic disease caused by a non-malignant tumor, or disease or symptoms secondary to the tumor, and can lead to higher medical risk and\u002For uncertainty in the evaluation of survival; Such as leukemoid reaction cancer (white blood cell count \\> 20 × 10 \\^ 9 L) , cachexia (known as weight loss of more than 10% 3 months before screening) , etc. .\n36. Known history of mental illness, substance abuse, alcohol or drug abuse.\n37. Women who are pregnant or nursing. The presence of any disease, treatment, or laboratory abnormality in the past or present may confuse the results of the study, affect the participant's participation in the study, or may not be in the best interest of the participant.","70 Years",{"count":114,"type":21},39,[24],"* Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.\n* Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.\n\nExploratory analysis of the association between the efficacy of the combination regimen and biomarkers.",[27],"2024-07-14",{"date":120,"type":47},"2024-07-19",{"date":122,"type":21},"2024-07",{"date":124,"type":21},"2026-06",{"name":126,"class":54},"West China Second University Hospital"]